Company shares are trading at $48.98 slightly over the 50 day moving average which is $45.77 and which is well above the 200 day moving average of $37.38. The 50 day moving average was up $3.21 and the 200 day average went up $11.60 or +31.03%. (NASDAQ:EXAS) shares saw light trading volume with 1,663K shares changing hands in the last trading session. Volume was down 47.30% under the stocks average daily volume.
Traders are a little more bullish of late if you watch the motion in short interest. The company realized a fall in short interest between September 15, 2017 and September 29, 2017 of -32.51%. Short shares decreased 5,295,292 over that period. The short-interest ratio decreased to 6.0 and the percentage of shorted shares is 0.10% as of September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (EXAS). As of the end of the quarter Shell Asset Management CO had sold a total of 300 shares trimming its holdings by 2.0%. The value of the investment in (EXAS) went from $544,000 to $710,000 increasing 30.5% quarter over quarter. As of quarter end SIT Investment Associates Inc had acquired 18,750 shares growing its position 168.2%. The value of the investment in EXAS increased from $394,000 to $1,409,000 a change of $1,015,000 for the reporting period.
As of quarter end Skylands Capital, LLC had disposed of a total of 75,150 shares trimming its stake by 24.1%. The value of the investment in Exact Sciences Corporation increased from $11,016,000 to $11,134,000 a change of 1.1% since the last quarter. As of quarter end Financial Architects, Inc had sold 450 shares trimming its position 56.3%. The value of the company’s investment in Exact Sciences Corporation went from $28,000 to $16,000 decreasing 42.9% quarter to quarter.
On July 20 Canaccord Genuity left the company rating at “Buy” but raised the price expectation from $26.00 to $42.00. October 3 investment analysts at Canaccord Genuity kept the company rating at “Buy” and raised the price target to $60.00 from $42.00.
As of the last earnings report the EPS was $-1.29 and is expected to be $-1.17 for the current year with 119,096,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.28 and the next full year EPS is anticipated to be $-0.72.
Exact Sciences Corporation, launched on February 10, 1995, is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. The Company offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer..